Reported Earlier, Zai Lab's TIVDAK Receives China NMPA Approval Based On Phase 3 innovaTV 301 Trial Demonstrating Statistically Significant Overall Survival Benefit

Loading news article.

Reported Earlier, Zai Lab's TIVDAK Receives China NMPA Approval Based On Phase 3 innovaTV 301 Trial Demonstrating Statistically Significant Overall Survival Benefit | WAPE

Reported Earlier, Zai Lab's TIVDAK Receives China NMPA Approval Based On Phase 3 innovaTV 301 Trial Demonstrating Statistically Significant Overall Survival Benefit

Article summary

Related companies

Comments —